Bevacizumab effective against macular oedema
Intravitreal ranibizumab appears to be an effective treatment for macular oedema secondary to retinal vein occlusion, according to the results of a prospective trial. The study involved 40 consecutive eyes of 41 patients with branch or central retinal vein occlusion. All received three initial intravitreal injections of 0.5mg ranibizumab at monthly intervals, with further retreatment based on visual acuity changes and OCT findings. In patients with branch retinal vein occlusion, the mean logMAR BCVA improved significantly from the baseline value 0.76 to 0.19 at 12 months’ follow-up (± 0.18 (p = 0.000). There was also an improvement in mean logMAR BCVA at 12 months among eyes with central retinal vein occlusion, from 0.84 to 0.39, although it did not reach statistical significance.
(Kim et al, Ophthalmologica 2012; DOI:10.1159/000334906).
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.